Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ALBANY, N.Y., June 18, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced the U.S. Food & Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to conduct a clinical study of the NanoKnife System for the ablation of focal prostate cancer.
Help employers find you! Check out all the jobs and post your resume.
